Recent first-in-human trials include Pheast and Auron, plus new targets from Immunocore and Cero.

J&J decides not to opt in to erzotabart, and Genmab pulls the plug.

The company has caught up with Syndax and overtaken Kura in the first-line menin inhibitor race.

A hit on EFS will challenge regulators, and points to Merck's design blunder in Keynote-585.

Could a new ADC project distract attention away from evorpacept?

The German group has posted a PFS win in phase 3, but overall survival was confounded by crossover.